SCHEDULE: Apollomics CEO Provides $2M Bridge Loan to Company

Apollomics Inc. Chairman and CEO Hung-Wen Chen has provided a $2 million unsecured bridge loan to the company, convertible into equity under specific future financing conditions.

Summary

• Chairman and CEO Hung-Wen Chen provided a $2 million unsecured bridge loan to Apollomics Inc. on March 30, 2026.
• The loan will automatically convert into equity upon the company's next financing round of at least $10 million.
• Conversion price is set at 80% of the lowest per-share purchase price in the next equity financing.
• If not converted within 18 months, the holder may elect to convert based on the 10-day average closing price prior to maturity.
• Reporting persons Hung-Wen Chen and King Regent Management Limited collectively hold 901,362 shares, representing 41.8% of the class.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it provides necessary liquidity, it highlights the company's ongoing need for external capital and potential future dilution.

Positives

• Demonstrates strong commitment and financial support from the CEO during a capital-intensive phase.
• Provides immediate liquidity to the company without immediate dilution to existing shareholders.
• The 80% conversion price mechanism provides an incentive for the CEO to support future successful financing rounds.

Negatives

• The need for a bridge loan indicates potential cash flow constraints or a requirement for additional working capital.
• Future conversion of the note will result in shareholder dilution.
• The company is reliant on future equity financing of at least $10 million to trigger the automatic conversion.

Risks

• Potential for significant dilution of existing shareholders upon conversion of the $2 million note.
• Liquidity risk if the company fails to secure the required $10 million in future equity financing.
• Concentration of ownership risk, as the CEO and his controlled entity already hold 41.8% of the class.

Future Outlook

The company intends to pursue a future equity financing round of at least $10 million, which will trigger the conversion of the CEO's bridge loan into equity.

Management Comments

• The transaction is structured as an unsecured bridge loan to support the company's capital requirements.

Industry Context

StockSavvy.ai notes that insider-led bridge financing is a common mechanism in the biotech and emerging growth sectors to bridge the gap between clinical milestones or funding rounds, though it often signals that the company is currently burning cash and requires external capital to maintain operations.

Comparison to Industry Standards

• Bridge loans from insiders are standard practice for small-cap biotech firms facing capital constraints.
• The 20% discount on conversion price is consistent with market standards for convertible bridge notes in the life sciences sector.

Corporate Governance

Related Party Transactions

• The $2 million bridge loan was provided by the company's Chairman and CEO, Hung-Wen Chen.

Stakeholder Impact

• Shareholders face potential dilution upon the conversion of the note.
• Creditors may be impacted by the addition of $2 million in unsecured debt.

Next Steps

• Execution of a future equity financing round of at least $10 million.
• Potential conversion of the $2 million note into Class A ordinary shares.

Key Dates

Recommendation

The reliance on insider bridge financing suggests a tight cash position, warranting a hold until the company successfully completes the required $10 million equity financing round.

Keywords

Apollomics, Bridge Loan, Convertible Note, Equity Financing, Insider Financing, APLM